$2.47T
Total marketcap
$72.26B
Total volume
BTC 50.60%     ETH 15.17%
Dominance

Teva Pharmaceutical Industries Limited 0LER.IL Stock

13.23 USD {{ price }} -2.757353% {{change_pct}}%
Exchange
IOB
Market Cap
18.29B USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
1.5K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.9 USD

Teva Pharmaceutical Industries Limited Price Chart

Teva Pharmaceutical Industries Limited 0LER.IL Financial and Trading Overview

Teva Pharmaceutical Industries Limited stock price 13.23 USD
Previous Close 9.55 USD
Open 0 USD
Bid 8.92 USD x 0
Ask 0 USD x 0
Day's Range 0 - 0 USD
52 Week Range 0 - 11.25 USD
Volume 170 USD
Avg. Volume 27.37K USD
Market Cap 10.8B USD
Beta (5Y Monthly) 1.199515
PE Ratio (TTM) N/A
EPS (TTM) -1.9 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 10.22 USD

0LER.IL Valuation Measures

Enterprise Value 29.71B USD
Trailing P/E N/A
Forward P/E 3.763672
PEG Ratio (5 yr expected) 1.71
Price/Sales (ttm) 0.71915716
Price/Book (mrq) 1.5310663
Enterprise Value/Revenue 1.978
Enterprise Value/EBITDA 8.003

Trading Information

Teva Pharmaceutical Industries Limited Stock Price History

Beta (5Y Monthly) 1.199515
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 11.25 USD
52 Week Low 0 USD
50-Day Moving Average 8.35 USD
200-Day Moving Average 8.92 USD

0LER.IL Share Statistics

Avg. Volume (3 month) 27.37K USD
Avg. Daily Volume (10-Days) 10.99K USD
Shares Outstanding 1.12B
Float 1.12B
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 49.62%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) June 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -14.87%
Operating Margin (ttm) 16.52%
Gross Margin 45.39%
EBITDA Margin 24.71%

Management Effectiveness

Return on Assets (ttm) 3.48%
Return on Equity (ttm) -26.58%

Income Statement

Revenue (ttm) 15.02B USD
Revenue Per Share (ttm) 13.47 USD
Quarterly Revenue Growth (yoy) 2.39%
Gross Profit (ttm) 6.97B USD
EBITDA 3.71B USD
Net Income Avi to Common (ttm) -2233999872 USD
Diluted EPS (ttm) -1.95
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.67B USD
Total Cash Per Share (mrq) 2.38 USD
Total Debt (mrq) 21.02B USD
Total Debt/Equity (mrq) 272.65 USD
Current Ratio (mrq) 1.021
Book Value Per Share (mrq) 6.293

Cash Flow Statement

Operating Cash Flow (ttm) 1.7B USD
Levered Free Cash Flow (ttm) 3.08B USD

Profile of Teva Pharmaceutical Industries Limited

Country United Kingdom
State N/A
City Tel Aviv
Address 124 Dvora Hanevi’a Street
ZIP 6944020
Phone 972 3 914 8213
Website https://www.tevapharm.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees 34004

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Q&A For Teva Pharmaceutical Industries Limited Stock

What is a current 0LER.IL stock price?

Teva Pharmaceutical Industries Limited 0LER.IL stock price today per share is 13.23 USD.

How to purchase Teva Pharmaceutical Industries Limited stock?

You can buy 0LER.IL shares on the IOB exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Teva Pharmaceutical Industries Limited?

The stock symbol or ticker of Teva Pharmaceutical Industries Limited is 0LER.IL.

Which industry does the Teva Pharmaceutical Industries Limited company belong to?

The Teva Pharmaceutical Industries Limited industry is Drug Manufacturers-Specialty & Generic.

How many shares does Teva Pharmaceutical Industries Limited have in circulation?

The max supply of Teva Pharmaceutical Industries Limited shares is 1.38B.

What is Teva Pharmaceutical Industries Limited Price to Earnings Ratio (PE Ratio)?

Teva Pharmaceutical Industries Limited PE Ratio is now.

What was Teva Pharmaceutical Industries Limited earnings per share over the trailing 12 months (TTM)?

Teva Pharmaceutical Industries Limited EPS is -1.9 USD over the trailing 12 months.

Which sector does the Teva Pharmaceutical Industries Limited company belong to?

The Teva Pharmaceutical Industries Limited sector is Healthcare.